Sanofi SA (SNY) News & EventsSNYNews & EventsSanofi SA

Novavax Secures Approval for Nuvaxovid Targeting SARS-CoV-2 XFG Variant

Novavax's (NVAX) partners have received approvals for the Nuvaxovid formulation to target the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets including the U.S., European Union and Japan. These approvals position Novavax to continue earning royalties on net sales in these markets this season. Sanofi (SNY), Novavax's largest partner, leads Nuvaxovid commercial activities across most major markets and looks to be positioned for a robust 2026-2027 season, expanding the vaccine's commercial reach through broader activities in the U.S. and launches in Germany, Canada and other international markets from 2026 onward. Novavax is eligible to receive ongoing royalties from sales of the vaccine per their 2024 collaboration and license agreement. Takeda (TAK) commercializes Nuvaxovid in Japan. In the 2025-2026 season, Nuvaxovid was the second-most used COVID-19 vaccine in Japan, with delivery volumes and the number of sites receiving the vaccine increasing significantly year over year. Under the CLA terms announced in May 2025, Novavax earns annual milestones tied to regulatory approvals and royalties on net sales each season.

Major Averages Mixed at Open Amid Middle East Uncertainty

The major averages were mixed near noon to start the week, as traders are beginning to doubt that the U.S. and Iran will reach a lasting agreement to end the war in the near term. Balancing the negative sentiment around conflict in the Middle East are strong corporate earnings and optimism around AI spending.Iran is saying it is nearing an agreement with Oman on new shipping lanes but maintaining conditions that could delay a broader reopening. Meanwhile, Iranian Foreign Minister Abbas Araghchi said over the weekend that there was "no possibility of restarting negotiations" with the U.S. as long as Washington continues to violate the June memorandum of understanding. Oil prices were higher after the news.The market is also digesting last week's unexpectedly weak July jobs report, which showed payrolls fell by 23,000 and included substantial downward revisions to prior months. The report reduced expectations for a September Fed rate hike, but the outlook remains uncertain because inflation data due this week could complicate the picture. Investors will get the July CPI report Tuesday, followed by the PPI report later in the week.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Intelannounced aof common stockMetaunveiled open sourceGameStop'sRyan Cohen is considering withdrawing the company's $56B bid for eBay,Archer AviationBoeing'sWisk Aero, SkyGrid, and Insitu subsidiariesMonday.comreportedand reaffirmed its FY26 revenue guidance2. WALL STREET CALLS:JefferiesAppleto Underperform on apparent all-glass iPhone cancellationSanDiskto Buy at Argus on strong fundamentals and valuationDoximityto Underweight at Wells FargoHPEto Overweight at Morgan Stanley on server and storage spendingWall Streetof Csquarewith mostlybullish ratings3. AROUND THE WEB:Amazonis planning to invest in a large natural gas power plant to supply electricity directly to a major AI data center in Texas, underscoring how rapidly rising AI compute demand is driving tech companies to secure dedicated power generation, NYT reportsSonyand (TSMC) plan to spend around 1 trillion yen, or $6.32B, to jointly make next generation microchips used in image sensors, Nikkei Asia saysMicrosoftplans to significantly ramp production of its next-generation in-house AI chips next year, aiming to win adoption from major cloud customers such as Anthropic despite slow uptake of the current-generation chips, The Information reportsSanofiis facing shortages of Myozyme and Nexviazyme for Pompe disease after manufacturing and quality-control issues at its Waterford facility, which was cited by the FDA in June for violations involving production of other medicines, STAT saysImperial Brandsis preparing to cut thousands of jobs across the U.S. and Europe as part of a cost-cutting initiative, Bloomberg reports4. MOVERS:Bowman Consultinggains after announcing it will befor $43 per share and reporting Q2 resultsVarex Imagingincreases after announcing Teledynewillfor $18.90 per share in cash and reporting Q3 resultsMarineMaxhigher after announcing it will befor $53 per share in cashPowerFleetfalls afterand cutting its guidance for FY27Lincoln Educationaland Bitdeerlower after5. EARNINGS/GUIDANCE:Surgery Partnersand backed its guidance for FY26N-ableand provided guidance for Q3 and FY26Aaonand raised its outlook for FY26, with CEO Matt Tobolski contending the results "demonstrate the continued strength of demand for our solutions and the progress we are making scaling the company to meet that demand"Monday.comand reaffirmed its outlook for FY26Accendra Healthand cut its outlook for FY26INDEXES:Near midday, the Dow was down 20.58, or 0.04%, to 54,016.35, the Nasdaq was down 18.40, or 0.07%, to 26,672.22, and the S&P 500 was up 9.16, or 0.12%, to 7,766.80.